ResTORbio debuts IPO
Boston-based ResTORbio Inc, a clinical-stage biopharmaceutical company focused on treating aging-related diseases, has debuted its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “TORC." BofA Merrill Lynch, Leerink Partners and Evercore ISI are the lead underwriters. ResTORbio's pre-IPO includes include OrbiMed, Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.
26 January 2018•2 mins read
